Skip to content

LEXARIA BIOSCIENCE CORP.: 10-Q filed 2023-04-14

What LEXARIA BIOSCIENCE CORP. reported in its quarterly report filed 2023-04-14 (fiscal Q2 2023): 30 published measures, 83 facts as tagged in accession 0001640334-23-000636.

This filing

Form
10-Q (quarterly report)
Filed
2023-04-14
Fiscal period
fiscal Q2 2023
Accession
0001640334-23-000636 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All LEXARIA BIOSCIENCE CORP. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-02-284,854,979USD
At 2022-08-317,833,927USD
At 2022-02-2811,414,564USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-02-28223,131USD
At 2022-08-31201,437USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-02-284,974,131USD
At 2022-08-317,948,904USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-02-283,272,102USD
At 2022-08-315,813,218USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2022-12-01 to 2023-02-28-1,298,131USD90
2022-09-01 to 2023-02-28-3,054,075USD181
2022-09-01 to 2022-11-30-1,755,944USD91
2021-12-01 to 2022-02-28-1,425,776USD90
2021-09-01 to 2022-02-28-3,418,933USD181
2021-09-01 to 2021-11-30-1,993,157USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2022-09-01 to 2023-02-28-2,473,590USD181
2021-09-01 to 2022-02-28-2,443,594USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2022-09-01 to 2023-02-2833,748USD181
2021-09-01 to 2022-02-2842,375USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2022-12-01 to 2023-02-2835,015USD90
2022-09-01 to 2023-02-28136,491USD181
2021-12-01 to 2022-02-2830,650USD90
2021-09-01 to 2022-02-2844,530USD181

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2022-09-01 to 2023-02-28136,491USD181
2021-09-01 to 2022-02-2844,530USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2022-09-01 to 2023-02-280USD181
2021-09-01 to 2022-02-28-22,191USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2022-09-01 to 2023-02-28-67,526USD181
2021-09-01 to 2022-02-28-92,638USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-02-28-42,152,603USD
At 2022-08-31-39,098,528USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2023-02-28301,421USD
At 2022-08-31315,505USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2022-09-01 to 2023-02-2879,302USD181
2021-09-01 to 2022-02-28408,544USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-02-284,003,781USD
At 2022-08-316,977,516USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-02-28223,131USD
At 2022-08-31194,036USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2023-02-28136,796USD
At 2022-08-31201,784USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2022-12-01 to 2023-02-281,342,695USD90
2022-09-01 to 2023-02-283,197,682USD181
2021-12-01 to 2022-02-281,472,936USD90
2021-09-01 to 2022-02-283,484,728USD181

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2023-02-287,588USD
At 2022-08-3138,418USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2022-12-01 to 2023-02-2832,057USD90
2022-09-01 to 2023-02-28117,738USD181
2021-12-01 to 2022-02-2824,263USD90
2021-09-01 to 2022-02-2832,573USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2022-12-01 to 2023-02-28696,178USD90
2022-09-01 to 2023-02-281,525,667USD181
2021-12-01 to 2022-02-28275,686USD90
2021-09-01 to 2022-02-28734,395USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-02-285,950,998shares
At 2022-08-315,950,998shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-02-283,272,102USD
At 2022-08-315,813,218USD
At 2022-02-288,359,374USD
At 2021-08-3110,917,797USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2023-02-2847,120,783USD
At 2022-08-3147,041,481USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2023-02-284,631,848USD
At 2022-11-305,931,960USD
At 2022-08-317,632,490USD
At 2022-02-2811,219,941USD
At 2021-11-3011,468,614USD
At 2021-08-3113,063,552USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2023-02-28427,890USD
At 2022-08-31379,993USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2022-12-01 to 2023-02-28-1,310,638USD90
2022-09-01 to 2023-02-28-3,079,944USD181
2021-12-01 to 2022-02-28-1,448,673USD90
2021-09-01 to 2022-02-28-3,452,155USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2022-12-01 to 2023-02-28646,517USD90
2022-09-01 to 2023-02-281,672,015USD181
2021-12-01 to 2022-02-281,197,250USD90
2021-09-01 to 2022-02-282,750,333USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2022-09-01 to 2023-02-28-64,988USD181
2021-09-01 to 2022-02-28164,221USD181

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2022-09-01 to 2023-02-28-33,713USD181
2021-09-01 to 2022-02-281,161USD181

Inspect the source

Entity
LEXARIA BIOSCIENCE CORP. / CIK 0001348362
Captured
2026-09-20T07:55:03.045Z
SEC response SHA-256
c8696dbfbdb8ee1a7522ea5b45a8c2d45cb12720b3d84857c1cda6bba2861389

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001348362.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))